Clinical Trials Management Today's Research... Tomorrow's Cures

Relationships & Accomplishments

New Data Confirms Strong and Long-Lasting Protection of Johnson & Johnson COVID-19 Vaccine

September 21, 2021 | Posted in: Relationships & Accomplishments
Johnson & Johnson Announces Real-World Evidence and Phase 3 Data Confirming Strong and Long-Lasting Protection of Single-Shot COVID-19 Vaccine in the U.S. Additional data ... » Read More


Myovant Sciences Announces European Commission Approval for RYEQO®

July 21, 2021 | Posted in: Relationships & Accomplishments
Myovant Sciences Announces European Commission Approval for RYEQO® for the Treatment of Women With Uterine Fibroids July 20, 2021 02:00 ET | Source: Myovant Sciences, Inc. ... » Read More


Positive New Data for Johnson & Johnson Single-Shot COVID-19 Vaccine

July 7, 2021 | Posted in: Relationships & Accomplishments
Positive New Data for Johnson & Johnson Single-Shot COVID-19 Vaccine on Activity Against Delta Variant and Long-lasting Durability of Response Demonstrated stron... » Read More


SCYNEXIS Announces FDA Approval of BREXAFEMME®

June 7, 2021 | Posted in: Relationships & Accomplishments
SCYNEXIS Announces FDA Approval of BREXAFEMME® (ibrexafungerp tablets) as the First and Only Oral Non-Azole Treatment for Vaginal Yeast Infections June 02, 2021 07:30 ET | Source: ... » Read More


Dermavant Submits New Drug Application (NDA) to FDA for Tapinarof Cream

June 7, 2021 | Posted in: Relationships & Accomplishments
June 3, 2021 Dermavant Submits New Drug Application (NDA) to FDA for Tapinarof Cream for the Treatment of Adults with Plaque Psoriasis – NDA is supported by positive data from the Pha... » Read More


Myovant Sciences and Pfizer Receive FDA Approval for MYFEMBREE®

May 27, 2021 | Posted in: Relationships & Accomplishments
Myovant Sciences and Pfizer Receive FDA Approval for MYFEMBREE®, the First Once-Daily Treatment for Heavy Menstrual Bleeding Associated With Uterine Fibroids May 26, 2021 at 4:15 PM EDT ... » Read More


Incyte Announces Positive Results from Phase 3 TRuE-V Program

May 19, 2021 | Posted in: Relationships & Accomplishments
Incyte Announces Positive Results from Phase 3 TRuE-V Program Evaluating Ruxolitinib Cream in Patients with Vitiligo May 17, 2021  DownloadPDF Format (opens in new window) ... » Read More


Phathom Pharmaceuticals Announces HP-301 Topline Results

May 5, 2021 | Posted in: Relationships & Accomplishments
Phathom Pharmaceuticals Announces Positive Topline Results from Pivotal Phase 3 Trial of Vonoprazan in Helicobacter pylori (H. pylori) Infection; Study Met All Primary and Secondary Endpoints A... » Read More


Amgen Announces Positive Top-Line Results From Otezla® (apremilast) Phase 3 ADVANCE Study In Mild-To-Moderate Plaque Psoriasis

May 11, 2020 | Posted in: Relationships & Accomplishments
Otezla Treatment Resulted in Significant Improvements in Measures of Mild-to-Moderate Psoriasis Compared With Placebo Data Will be Submitted to the U.S. Food and Drug Administration (FDA) for I... » Read More


Evofem Biosciences Announces Positive Top-Line Results of Phase 3 Study Evaluating Amphora for Hormone-Free Birth Control

December 26, 2018 | Posted in: Relationships & Accomplishments
– Top-Line Phase 3 Data Demonstrate 86.0% Efficacy, which Met Primary Study Endpoint, and 98.7% Efficacy when Used as Directed – – Q2 2019 New Drug Application (NDA) Resubmiss... » Read More


« Previous 1 2 Next »